Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001042 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT00001042 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 112 participants.
The verdict
NCT00001042, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
To determine in healthy HIV-negative volunteers the safety and immunogenicity of rgp120/HIV-1SF2 (BIOCINE) formulated with each of seven adjuvants. PER AMENDMENT 3/6/96: Purpose of the extension study - To determine the ability of immunization with rgp 120/SF-2 to induce an HIV-1 envelope-specific delayed-type hypersensitivity (DTH) response in volunteers who receive rsgp 120/MN skin testing. One approach to improve the immunogenicity of an HIV-1 subunit protein vaccine is to combine the immunogen with an adjuvant. Adjuvants may augment vaccine immunogenicity by several mechanisms, and as a result induce a more favorable antibody response with high titers, which appear earlier in the course of immunization and persist over time.
Interventions
- BIOLOGICAL MF59
- BIOLOGICAL Aluminum hydroxide
- BIOLOGICAL Lipid A, Monophosphoryl
- BIOLOGICAL Lipid A, Liposome-encapsulated monophosphoryl
- BIOLOGICAL Syntex adjuvant formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Est. Completion | 1996-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001042
The ClinicalTrials.gov registry entry for NCT00001042 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MF59 is the first listed.
NCT00001042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001042 about?
NCT00001042 is a clinical study titled "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals". To determine in healthy HIV-negative volunteers the safety and immunogenicity of rgp120/HIV-1SF2 (BIOCINE) formulated with each of seven adjuvants. PER AMENDMENT 3/6/96: Purpose of the extension study - To determine the ability of immunization with rgp 120/SF-2 to induce an HIV-1 envelope-specific ...
What is the current status of trial NCT00001042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. Estimated completion is 1996-03.
What interventions are being tested in trial NCT00001042?
The interventions under investigation include: MF59 (BIOLOGICAL), Aluminum hydroxide (BIOLOGICAL), Lipid A, Monophosphoryl (BIOLOGICAL), Lipid A, Liposome-encapsulated monophosphoryl (BIOLOGICAL), Syntex adjuvant formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001042?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.